|1.||Rabe, Klaus F: 11 articles (01/2014 - 02/2002)|
|2.||Giembycz, Mark A: 7 articles (01/2015 - 01/2005)|
|3.||Calverley, Peter M A: 7 articles (01/2014 - 01/2007)|
|4.||Lahu, Gezim: 7 articles (11/2013 - 08/2008)|
|5.||Bredenbröker, Dirk: 6 articles (01/2014 - 08/2005)|
|6.||Bäumer, Wolfgang: 6 articles (01/2012 - 06/2002)|
|7.||Houslay, Miles D: 6 articles (10/2009 - 11/2005)|
|8.||Kietzmann, Manfred: 6 articles (04/2007 - 06/2002)|
|9.||Hu, ChiaChi: 5 articles (07/2015 - 08/2012)|
|10.||Zhang, Han-Ting: 5 articles (01/2015 - 08/2004)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
06/01/2002 - "While most of these drugs are still in preclinical evaluation, some recent phase II-III clinical trials have shown the beneficial effects of a new class of anti-inflammatory compounds, the phosphodiesterase-4 (PDE-4) inhibitors, in patients with COPD. "
08/01/2015 - "Alternative strategies to treatment including phosphodiesterase-4 inhibition and long-term antibiotic treatment have become reasonable alternatives to more established approaches, at least in terms of preventing COPD exacerbations. "
10/01/2013 - "Inhibition of phosphodiesterase 4 (PDE4) represents an approach to anti-inflammatory therapy in chronic obstructive pulmonary disease (COPD). "
01/01/2011 - "[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors]."
02/01/2010 - "Zl-n-91, a selective phosphodiesterase 4 inhibitor, suppresses inflammatory response in a COPD-like rat model."
|2.||Asthma (Bronchial Asthma)
08/01/1998 - "Whether orally active safe phosphodiesterase 4 isoenzyme inhibitors will be useful in the treatment of asthma remains to be established."
04/01/2014 - "Compounds 1, 2, 5, and 8 showed inhibitory activities against phosphodiesterase-4 (PDE4), a therapeutic target of asthma, with IC50 values ranging from 2.57 to 8.94 μM. "
01/01/2014 - "The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma."
05/01/2012 - "Phosphodiesterase-4 (PDE4) has been identified to be a promising target for treatment of asthma. "
12/01/2010 - "Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma."
|3.||Atopic Dermatitis (Atopic Eczema)
07/01/2014 - "The safety and efficacy of topical E6005, a novel phosphodiesterase 4 inhibitor, in Japanese adults with atopic dermatitis were evaluated. "
08/14/1999 - "Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis."
07/01/2014 - "Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial."
07/01/2013 - "Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model."
10/01/2015 - "A novel approach for treating atopic dermatitis (AD) is the inhibition of phosphodiesterase 4 (PDE4), an enzyme involved in the proinflammatory cascade. "
11/01/2015 - "In chronic inflammation, prevention of cAMP degradation by phosphodiesterase-4 (PDE4) inhibition can be anti-inflammatory therapy. "
04/07/2015 - "Phosphodiesterase 4B (PDE4B) plays a key role in regulating inflammation. "
06/01/2012 - "Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation."
01/01/2012 - "Inhibitors of phosphodiesterase 4 (PDE4) are new anti-inflammatory drugs which cause cAMP accumulation in the cell and inhibit numerous stages of allergic inflammation. "
01/01/2012 - "Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation."
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
01/01/2015 - "Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis."
06/01/2013 - "Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases."
01/01/2016 - "In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis. "
01/01/2016 - "Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)."
07/01/2015 - "Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)."
|2.||Phosphodiesterase 4 Inhibitors
|5.||Anti-Inflammatory Agents (Anti-Inflammatories)
|5.||Homologous Transplantation (Allograft)